APA

Chen C., Chen C., Lin C., Lin C., Hu T., Tung S., Hsieh S., Lu S., Chien R., Hung C. & Sheen I. (20201027). Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. : Scientific reports.

Chicago

Chen Chun-Hsien, Chen Chien-Hung, Lin Chih-Lang, Lin Chun-Yen, Hu Tsung-Hui, Tung Shui-Yi, Hsieh Sen-Yung, Lu Sheng-Nan, Chien Rong-Nan, Hung Chao-Hung and Sheen I-Shyan. 20201027. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. : Scientific reports.

Harvard

Chen C., Chen C., Lin C., Lin C., Hu T., Tung S., Hsieh S., Lu S., Chien R., Hung C. and Sheen I. (20201027). Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. : Scientific reports.

MLA

Chen Chun-Hsien, Chen Chien-Hung, Lin Chih-Lang, Lin Chun-Yen, Hu Tsung-Hui, Tung Shui-Yi, Hsieh Sen-Yung, Lu Sheng-Nan, Chien Rong-Nan, Hung Chao-Hung and Sheen I-Shyan. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. : Scientific reports. 20201027.